Skip to main content

Advertisement

SpringerLink
Log in

Renal manifestations of the antiphospholipid syndrome

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

The antiphospholipid syndrome is characterized by recurrent arterial and venous thromboses and pregnancy morbidity in association with antiphospholipid antibodies. Recurrent thrombotic events are associated with significant morbidity and mortality. Renal involvement encompasses the whole renal vasculature and may lead to proteinuria, renal impairment, hypertension, and end-stage renal failure. Renal involvement is especially difficult to distinguish from glomerulonephritis when the antiphospholipid syndrome develops in patients with systemic lupus erythematosus. This article reviews the diagnosis and treatment of the major features of this syndrome, with particular reference to the kidney.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Hughes GR: Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. BMJ (Clin Res Ed) 1983, 287:1088–1089.

    Article  CAS  Google Scholar 

  2. Harris EN, Gharavi AE, Boey ML, et al.: Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983, 2:1211–1214.

    Article  PubMed  CAS  Google Scholar 

  3. Brandt JT, Triplett DA, Alving B, Scharrer I: Criteria for the diagnosis of lupus anticoagulants: an update on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995, 74:1185–1190.

    PubMed  CAS  Google Scholar 

  4. Cervera R, Khamashta MA, Font J, et al.: Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993, 72:113–124.

    CAS  Google Scholar 

  5. Cervera R, Piette JC, Font J, et al.: Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46:1019–1027.

    Article  PubMed  Google Scholar 

  6. Perez-Vazquez ME, Villa AR, Drenkard C, et al.: Influence of disease duration, continued followup and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus. J Rheumatol 1993, 20:437–442.

    PubMed  CAS  Google Scholar 

  7. Wilson W, Gharavi A, Koike T et al.: International consensus statement on preliminary classification for definite antiphospholipid syndrome. Report of an International Workshop. Arthritis Rheum 1999, 42:1309–1311.

    Article  PubMed  CAS  Google Scholar 

  8. Lockshin MD, Sammaritano LR, Schwartzman S: Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000, 43:440–443.

    Article  PubMed  CAS  Google Scholar 

  9. Miyakis S, Lockshin MD, Atsumi T, et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295–306.

    Article  PubMed  CAS  Google Scholar 

  10. Shah NM, Khamashta MA, Atsumi T, Hughes GR: Outcome of patients with anticardiolipin anti-bodies: a 10 year follow up of 52 patients. Lupus 1998, 7:3–6.

    Article  PubMed  CAS  Google Scholar 

  11. Jouhikainen T, Stephansson E, Leirisalo-Repo M: Lupus anticoagulant as a prognostic marker in systemic lupus erythematosus. Br J Rheumatol 1993, 32:568–573.

    Article  PubMed  CAS  Google Scholar 

  12. Schulman S, Svenungsson E, Granqvist S; the Duration of Anticoagulation Study Group: Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998, 104:332–338.

    Article  PubMed  CAS  Google Scholar 

  13. Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C: High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004, 164:77–82.

    Article  PubMed  Google Scholar 

  14. Finazzi G, Brancaccio V, Moia M, et al.: Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies. A four year prospective study from the Italian Registry. Am J Med 1996, 100:530–536.

    Article  PubMed  CAS  Google Scholar 

  15. Khamashta M, Cuadrado M, Mujic F, et al.: The management of thrombosis in the antiphospholipid -antibody syndrome. N Engl J Med 1995, 332:993–997.

    Article  PubMed  CAS  Google Scholar 

  16. Giron-Gonzalez JA, Garcia del Rio E, Rodriguez C, et al.: Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004, 31:1560–1567.

    PubMed  Google Scholar 

  17. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA: Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007, 109:422–430.

    Article  PubMed  CAS  Google Scholar 

  18. Roman MJ, Shanker BA, Davis A, et al.: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399–2406.

    Article  PubMed  CAS  Google Scholar 

  19. Medina G, Casaos D, Jara LJ, et al.: Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 2003, 62:607–610.

    Article  PubMed  CAS  Google Scholar 

  20. Baron MA, Khamashta MA, Hughes GR, D’Cruz DP: Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2005, 64:144–146.

    Article  PubMed  CAS  Google Scholar 

  21. Christodoulou C, Zain M, Bertolaccini ML, et al.: Prevalence of an abnormal ankle-brachial index in patients with antiphospholipid syndrome with pregnancy loss but without thrombosis: a controlled study. Ann Rheum Dis 2006, 65:683–684.

    Article  PubMed  CAS  Google Scholar 

  22. Sangle SR, D’Cruz DP, Jan W, et al.: Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann Rheum Dis 2003, 62:999–1002.

    Article  PubMed  CAS  Google Scholar 

  23. Sangle SR, Jan W, Lau IS, et al.: Coeliac artery stenosis and antiphospholipid (Hughes) syndrome/antiphospholipid anti-bodies. Clin Exp Rheumatol 2006, 24:349.

    Article  PubMed  CAS  Google Scholar 

  24. Vaz JL, Dancour MA, Bottino DA, Bouskela E: Nailfold videocapillaroscopy in primary antiphospholipid syndrome (PAPS). Rheumatology (Oxford) 2004, 43:1025–1027.

    Article  CAS  Google Scholar 

  25. Asherson RA, Khamashta MA, Ordi-Ros J, et al.: The primary antiphospholipid syndrome:major clinical and serological features. Medicine 1989, 68:366–374.

    Article  PubMed  CAS  Google Scholar 

  26. Hughes GR: The Prosser-White oration 1983. Connective tissue disease and the skin. Clin Exp Dermatol 1984, 9:535–544.

    Article  PubMed  CAS  Google Scholar 

  27. Ostuni PA, Lazzarin P, Pengo V, et al.: Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome. Ann Rheum Dis 1990, 49:184–187.

    Article  PubMed  CAS  Google Scholar 

  28. Hernandez D, Dominguez ML, Diaz F, et al.: Renal infarction in a severely hypertensive patient with lupus erythematosus and antiphospholipid antibodies. Nephron 1996, 72:298–301.

    Article  PubMed  CAS  Google Scholar 

  29. Asherson RA, Noble GE, Hughes GR: Hypertension, renal artery stenosis and the “primary” antiphospholipid syndrome. J Rheumatol 1991, 18:1413–1415.

    PubMed  CAS  Google Scholar 

  30. Ames PR, Cianciaruso B, Bellizzi V, et al.: Bilateral renal artery occlusion in a patient with primary antiphospholipid antibody syndrome: thrombosis, vasculitis or both? J Rheumatol 1992, 19:1802–1806.

    PubMed  CAS  Google Scholar 

  31. Rossi E, Sani C, Zini M, et al.: Anticardiolipin antibodies and renovascular hypertension. Ann Rheum Dis 1992, 51:1180–1181.

    Article  PubMed  CAS  Google Scholar 

  32. Mandreoli M, Zucchelli P: Renal vascular disease in patients with primary antiphospholipid antibodies. Nephrol Dial Transplant 1993, 8:1277–1280.

    PubMed  CAS  Google Scholar 

  33. Godfrey T, Khamashta MA, Hughes GR: Antiphospholipid syndrome and renal artery stenosis. QJM 2000, 93:127–129.

    Article  PubMed  CAS  Google Scholar 

  34. Cacoub P, Wechsler B, Piette JC, et al.: Malignant hypertension in antiphospholipid syndrome without overt lupus nephritis. Clin Exp Rheumatol 1993, 11:479–485.

    PubMed  CAS  Google Scholar 

  35. Sangle SR, D’Cruz DP, Abbs IC, et al.: Renal artery stenosis in hypertensive patients with antiphospholipid (Hughes) syndrome: outcome following anticoagulation. Rheumatology (Oxford) 2005, 44:372–377.

    Article  CAS  Google Scholar 

  36. Sipek-Dolnicar A, Hojnik M, Bozic B, et al.: Clinical presentations and vascular histopathology in autopsied patients with systemic lupus erythematosus and anticardiolipin antibodies. Clin Exp Rheumatol 2002, 20:335–342.

    PubMed  CAS  Google Scholar 

  37. Adler S, Szczech L, Qureshi A, et al.: IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clin Nephrol 2001, 56:428–434.

    PubMed  CAS  Google Scholar 

  38. Amigo MC, García-Torres R, Robles M, et al.: Renal involvement in primary antiphospholipid syndrome. J Rheumatol 1992, 19:1181.

    PubMed  CAS  Google Scholar 

  39. Nochy D, Daugas E, Droz D, et al.: The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 1999, 10:507–518.

    PubMed  CAS  Google Scholar 

  40. Calhoun WB, Hartshorne MF, Servilla KS, Tzamaloukas AH: Renal cortical perfusion defects caused by antiphospholipid syndrome seen on fusion imaging. Clin Nucl Med 2003, 28:853–854.

    Article  PubMed  Google Scholar 

  41. Leaker B, McGregor AO, Griffiths M, et al.: Insidious loss of renal function in patients with anticardiolipin antibodies and absence of overt nephritis. Br J Haematol 1991, 30:422–425.

    CAS  Google Scholar 

  42. Griffiths MH, Papadaki L, Neild GH: The renal pathology of primary antiphospholipid syndrome: a distinctive form of endothelial injury. QJM 2000, 93:457–467.

    Article  PubMed  CAS  Google Scholar 

  43. Tektonidou MG, Sotsiou F, Nakopoulou L, et al.: Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 2004, 50:2569–2579.

    Article  PubMed  Google Scholar 

  44. Kant KS, Pollak VE, Weiss MA, et al.: Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance. Medicine 1981, 60:71–86.

    Article  PubMed  CAS  Google Scholar 

  45. Glueck HI, Kant KS, Weiss MA, et al.: Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants. Arch Intern Med 1985, 145:1389–1395.

    Article  PubMed  CAS  Google Scholar 

  46. Moss KE, Isenberg DA: Comparison of renal disease severity and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone. Rheumatology (Oxford) 2001, 40:863–867.

    Article  CAS  Google Scholar 

  47. Daugas E, Nochy D, Huong du LT, et al.: Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 2002, 13:42–52.

    Article  PubMed  Google Scholar 

  48. Lai NS, Lan JL: Renal vein thrombosis in Chinese patients with systemic lupus erythematosus. Ann Rheum Dis 1997, 56:562–564.

    Article  PubMed  CAS  Google Scholar 

  49. Nied Prieto L, Suki NW: Frequent hemodyalisis graft thrombosis: association with antiphospholipid antibodies. Am J Kidney Dis 1994, 23:587–590.

    Google Scholar 

  50. Brunet P, Aillaud MF, San Marco M, et al.: Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int 1995, 48:794–800.

    Article  PubMed  CAS  Google Scholar 

  51. Stone JH, Amend WJ, Criswell LA: Antiphospholipid antibody syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus. Am J Kidney Dis 1999, 34:1040–1047.

    Article  PubMed  CAS  Google Scholar 

  52. Vaidya S, Wang CC, Gugliuzza C, Fish JC: Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies. Clin Transplant 1998, 12:439–444.

    PubMed  CAS  Google Scholar 

  53. Andrassy J, Zeier M, Andrassy K: Do we need screening for thrombophilia prior to kidney transplantation? Nephrol Dial Transplant 2004, 19(Suppl 4):iv64–68.

    Article  PubMed  Google Scholar 

  54. Lim W, Crowther MA, Eikelboom JW: Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006, 295:1050–1057.

    Article  PubMed  CAS  Google Scholar 

  55. Fihn SD, McDonell M, Martin D, et al.: Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993, 118:511–520.

    PubMed  CAS  Google Scholar 

  56. Finazzi G, Marchioli R, Brancaccio V, et al.: A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005, 3:848–853.

    Article  PubMed  CAS  Google Scholar 

  57. Crowther MA, Ginsberg JS, Julian J, et al.: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003, 349:1133–1138.

    Article  PubMed  CAS  Google Scholar 

  58. Cervera R, Khamashta MA, Shoenfeld Y, et al.: Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicenter prospective study of 1,000 patients. Ann Rheum Dis 2008 Sep 18 (Epub ahead of print).

  59. Bucciarelli S, Espinosa G, Cervera R, et al.: Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006, 54:2568–2576.

    Article  PubMed  Google Scholar 

  60. Hakim AJ, Machin SJ, Isenberg DA: Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: the response to splenectomy. Semin Arthritis Rheum 1998, 28:20–25.

    Article  PubMed  CAS  Google Scholar 

  61. Galindo M, Khamashta MA, Hughes GR: Splenectomy for refractory thrombocytopenia in the antiphospholipid syndrome. Rheumatology (Oxford) 1999, 38:848–853.

    Article  CAS  Google Scholar 

  62. Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ: Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). Lupus 2006, 15:877–880.

    Article  PubMed  CAS  Google Scholar 

  63. Girardi G, Yarilin D, Thurman JM, et al.: Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006, 203:2165–2175.

    Article  PubMed  CAS  Google Scholar 

  64. Petri M, Qazi U: Management of antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am 2006, 32:591–607.

    Article  PubMed  Google Scholar 

  65. Farquharson RG, Quenby S, Greaves M: Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002, 100:408–413.

    Article  PubMed  CAS  Google Scholar 

  66. Rai R, Cohen H, Dave M, Regan L: Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997, 314:253–257.

    PubMed  CAS  Google Scholar 

  67. Kutteh WH: Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996, 174:1584–1589.

    Article  PubMed  CAS  Google Scholar 

  68. Baglin T, Barrowcliffe TW, Cohen A, et al.: Guidelines on the use and monitoring of heparin. Br J Haematol 2006, 133:19–34.

    Article  PubMed  CAS  Google Scholar 

  69. Carlin AJ, Farquharson RG, Quenby SM, et al.: Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod 2004, 19:1211–1214.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Lupus Research Unit, The Rayne Institute, St. Thomas’ Hospital, London, SE1 7EH, UK

    David D’Cruz

Authors
  1. David D’Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David D’Cruz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

D’Cruz, D. Renal manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep 11, 52–60 (2009). https://doi.org/10.1007/s11926-009-0008-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-009-0008-2

Keywords

Search

Navigation